[Regional lymphotropic antibiotic therapy as a part of comprehensive treatment of children with purulent-inflammatory diseases of maxillofacial region].
126 children (aged 3-14 years) with severe purulent-inflammatory maxillofacial lesions underwent complex treatment: lymhotropic method of antibiotic (cefamabol) therapy was used in 64 of them. Clinical, microbiological and pharmacokinetic investigations have shown the method of lymphotropic regional antibiotic therapy to be effective and feasible to treat purulent-inflammatory maxillofacial lesions in children.
Zhanalina
B S
BS
D000038:Abscess / Q000188:drug therapy* / Q000378:metabolism; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002435:Cefamandole / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002481:Cellulitis / Q000188:drug therapy* / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D007571:Jaw Diseases / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D013492:Suppuration / Q000188:drug therapy / Q000378:metabolism; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D002435:Cefamandole